4.7 Article

Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference

期刊

KIDNEY INTERNATIONAL
卷 98, 期 2, 页码 294-309

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2020.04.020

关键词

acute kidney disease; acute kidney injury; fluid management; nephrotoxicity; renal replacement therapy; risk stratification

资金

  1. KDIGO
  2. Akebia Therapeutics
  3. Angion
  4. AMPharma
  5. AstraZeneca
  6. Astute Medical
  7. Atox Bio
  8. Baxter
  9. bioMerieux
  10. BioPorto
  11. Boehringer Ingelheim
  12. CytoSorbents
  13. Edwards
  14. Fresenius Medical Care
  15. GE Healthcare
  16. Grifols
  17. Kyowa Kirin
  18. Novartis
  19. NxStage
  20. Outset
  21. Potrero

向作者/读者索取更多资源

In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) published a guideline on the classification and management of acute kidney injury (AKI). The guideline was derived from evidence available through February 2011. Since then, new evidence has emerged that has important implications for clinical practice in diagnosing and managing AKI. In April of 2019, KDIGO held a controversies conference entitled Acute Kidney Injury with the following goals: determine best practices and areas of uncertainty in treating AKI; review key relevant literature published since the 2012 KDIGO AKI guideline; address ongoing controversial issues; identify new topics or issues to be revisited for the next iteration of the KDIGO AKI guideline; and outline research needed to improve AKI management. Here, we present the findings of this conference and describe key areas that future guidelines may address.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据